1Galletto-Lacour, Zamora SA, Gervaix A. Bedside procalcitionin and C-reactive protein test in children with fever without localizing signs of infection seen in a referal center [ J ]. pediatrics, 2003,112 (5) : 1054-1060.
8Kapsoritakis AN, Koukourakis MI, Sfiridaki A, et al. Mean platelet volume a useful marker of inflammatory bowel disease activity[J]. Am J Gastroe tevo1,2001,96 ( 3 ) :776-781.
4Fabijanic D,Banic M,Kardum D. C-reactive protein in cardiovascular risk evaluation [ J ]. Lijec Vjesn, 2006,128 (5/ 6) : 167-174.
5Selwyn AP. Antiatherosclerotic effects of statins : LDL versus non-LDL effects [ J ]. Curr Atheroscler Rep,2007,9 (4) :281- 285.
6Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation[ J]. N Engl J Med, 1999,340 (6) :448-454.
7Libby P. Inflammatory mechanisms: the molecular basis of inflammation and disease [ J ]. Nutr Rev,2007,65 ( 12 Pt 2) : S140-S146.
8Takahashi H. High-sensitivity C-reactive protein (CRP) assay - a novel method for assessment of risk ratios for atherosclerotic vascular diseases [ J ]. Rinsho Byori, 2002,50 ( 1 ) : 30-39.
9Yosef-LeviGrad E, Danenberg HD. C-reactive protein and atherothrombosis - a prognostic factor or a risk factor? [ J ]. Harefuah ,2007,146 (12) :970-974.
10Ursella S,Mazzone M,Portale G,et al. How to use the C-reactive protein in cardiac disease? [ J]. Minerva Cardioangiol,2005,53( 1 ) :59-68.
